Malignant Eye Neoplasm — Trials

Malignant Eye Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

446 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 83
Recruiting: 44
Ph III recruiting: 10
Growth YoY: —
Industry share: 30%
Top sponsor: IDEAYA Biosciences
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (67)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04960891	A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp(Non Applicable)	available	—	—	Immunocore LtdINDUSTRY	0	Jan 21, 2022	clinicaltrials

Data updated 22 days agoSource updated Jan 21, 2022source: clinicaltrials